T1	Participants 664 813	235 eligible patients initially registered, 91 were randomized to receive maintenance therapy, including seven patients who were no longer responding
T2	Participants 478 649	small-cell lung cancer (SCLC) patients who responded to six courses of induction chemotherapy with ifosfamide, etoposide, and an anthracycline (doxorubicin or epirubicin).
